Work

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Year: 2019

Type: erratum

Abstract: Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

Source: Leukemia

DOI: 10.1038/s41375-019-0410-3

Authors: C. S. Chim, S. K. Kumar, R. Z. Orlowski, G. Cook, P. G. Richardson, M. A. Gertz, S. Giralt, M. V. Mateos, X. Leleu, K. C. Anderson

Institutions: Queen Mary Hospital, University of Hong Kong, Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of Leeds, Harvard University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Universidad de Salamanca, Centre Hospitalier Universitaire de Poitiers

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,390

Funders: Amgen, Bristol-Myers Squibb, Sanofi, Teva Pharmaceutical Industries, Celgene, Amyloidosis Foundation, Pharmacyclics, Cilag

OpenAlex ID: W2962684406

Cites:

Cited by: 4

Related to: 10